Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate?

Barbui T, Carobbio A, Ferrari A.

Blood Adv. 2019 Dec 10;3(23):3951-3952. doi: 10.1182/bloodadvances.2019001159. No abstract available.

PMID:
31805188
2.

Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study).

Brucato A, Ferrari A, Tiraboschi M, Zucchi A, Cogliati C, Torzillo D, Dentali F, Tavecchia L, Gessi V, Squizzato A, Moretti S, Permunian ET, Carobbio A, Pasina L, De Stefano F, Tombetti E, Cumetti D, Tognoni G, Barbui T.

Eur J Intern Med. 2019 Nov 19. pii: S0953-6205(19)30355-3. doi: 10.1016/j.ejim.2019.10.016. [Epub ahead of print]

3.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases.

Sant'Antonio E, Guglielmelli P, Pieri L, Primignani M, Randi ML, Santarossa C, Rumi E, Cervantes F, Delaini F, Carobbio A, Betti S, Rossi E, Lavi N, Harrison CN, Curto-Garcia N, Gisslinger H, Gisslinger B, Specchia G, Ricco A, Vianelli N, Polverelli N, Koren-Michowitz M, Ruggeri M, Girodon F, Ellis M, Iurlo A, Mannelli F, Mannelli L, Sordi B, Loscocco GG, Cazzola M, De Stefano V, Barbui T, Tefferi A, Vannucchi AM.

Am J Hematol. 2019 Nov 12. doi: 10.1002/ajh.25677. [Epub ahead of print]

PMID:
31721282
4.

Sino-Nasal Anatomical Variations in Rhinogenic Headache Pathogenesis.

Sollini G, Mazzola F, Iandelli A, Carobbio A, Barbieri A, Mora R, Peretti G.

J Craniofac Surg. 2019 Jul;30(5):1503-1505. doi: 10.1097/SCS.0000000000005239.

PMID:
31299754
5.

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T.

Blood Adv. 2019 Jun 11;3(11):1729-1737. doi: 10.1182/bloodadvances.2019000211. Review.

6.

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.

Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G.

Leukemia. 2019 Aug;33(8):1996-2005. doi: 10.1038/s41375-019-0487-8. Epub 2019 May 29.

PMID:
31142846
7.

Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis.

Ferrari A, Carobbio A, Masciulli A, Ghirardi A, Finazzi G, De Stefano V, Vannucchi AM, Barbui T.

Haematologica. 2019 Dec;104(12):2391-2399. doi: 10.3324/haematol.2019.221234. Epub 2019 May 23.

8.

Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study.

Gritti P, Zangari R, Carobbio A, Zucchi A, Lorini FL, Ferri F, Agostinis C, Lanterna LA, Brembilla C, Foresti C, Barbui T, Biroli F.

World Neurosurg. 2019 Aug;128:e531-e540. doi: 10.1016/j.wneu.2019.04.190. Epub 2019 Apr 30.

PMID:
31048051
9.

Sino-Nasal Anatomical Variations in Rhinogenic Headache Pathogenesis: A Case-Control Clinical Study.

Sollini G, Mazzola F, Iandelli A, Carobbio A, Barbieri A, Mora R, Peretti G.

J Craniofac Surg. 2019 Feb 20. doi: 10.1097/SCS.0000000000005239. [Epub ahead of print]

PMID:
30817544
10.

Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.

De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Nov 12;8(11):112. doi: 10.1038/s41408-018-0151-y.

11.

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.

De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, Tieghi A, Lunghi F, Loscocco GG, Cattaneo D, Cortelezzi A, Betti S, Rossi E, Finazzi G, Censori B, Cazzola M, Bellini M, Arellano-Rodrigo E, Bertozzi I, Sadjadian P, Vianelli N, Scaffidi L, Gomez M, Cacciola E, Vannucchi AM, Barbui T.

Blood Cancer J. 2018 Feb 28;8(3):25. doi: 10.1038/s41408-018-0048-9.

12.

Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review.

Marchetti M, Carobbio A, Capitoni E, Barbui T.

Am J Hematol. 2018 May;93(5):698-703. doi: 10.1002/ajh.25049. Epub 2018 Feb 10.

13.

Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data.

Ghirardi A, Carobbio A, Masciulli A, Barbui T.

Blood Cancer J. 2018 Jan 16;8(1):5. doi: 10.1038/s41408-017-0038-3. No abstract available.

14.

Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit.

Buoro S, Manenti B, Seghezzi M, Dominoni P, Barbui T, Ghirardi A, Carobbio A, Marchesi G, Riva I, Nasi A, Ottomano C, Lippi G.

J Clin Pathol. 2018 Apr;71(4):330-335. doi: 10.1136/jclinpath-2017-204643. Epub 2017 Aug 20.

PMID:
28824010
15.

A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.

Barbui T, Vannucchi AM, Finazzi G, Finazzi MC, Masciulli A, Carobbio A, Ghirardi A, Tognoni G.

Am J Hematol. 2017 Nov;92(11):1131-1136. doi: 10.1002/ajh.24851. Epub 2017 Jul 29.

16.

Robotic Transnasal Endoscopic Skull Base Surgery: Systematic Review of the Literature and Report of a Novel Prototype for a Hybrid System (Brescia Endoscope Assistant Robotic Holder).

Bolzoni Villaret A, Doglietto F, Carobbio A, Schreiber A, Panni C, Piantoni E, Guida G, Fontanella MM, Nicolai P, Cassinis R.

World Neurosurg. 2017 Sep;105:875-883. doi: 10.1016/j.wneu.2017.06.089. Epub 2017 Jun 20.

PMID:
28645603
17.

Echocardiographic outflow pump ramp test in centrifugal-flow left ventricular assist device.

Iacovoni A, Vittori C, Fontana A, Carobbio A, Fino C, D'Elia E, Terzi A, Senni M.

Int J Artif Organs. 2017 Apr 18:0. doi: 10.5301/ijao.5000573. [Epub ahead of print]

PMID:
28430303
18.

No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.

Barbui T, Carobbio A, Ghirardi A, Masciulli A, Rambaldi A, Vannucchi AM.

Haematologica. 2017 Jun;102(6):e219-e221. doi: 10.3324/haematol.2017.165126. Epub 2017 Mar 2. Review. No abstract available.

19.

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera.

Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, Leone R, Mantovani A, Barbui T, Rambaldi A.

J Hematol Oncol. 2017 Feb 22;10(1):54. doi: 10.1186/s13045-017-0425-z.

20.

Diagnostic impact of the 2016 revised who criteria for polycythemia vera.

Barbui T, Thiele J, Gisslinger H, Carobbio A, Vannucchi AM, Tefferi A.

Am J Hematol. 2017 May;92(5):417-419. doi: 10.1002/ajh.24684. Epub 2017 Mar 4. No abstract available.

21.

ACE inhibitors and cytoreductive therapy in polycythemia vera.

Barbui T, Masciulli A, Ghirardi A, Carobbio A.

Blood. 2017 Mar 2;129(9):1226-1227. doi: 10.1182/blood-2016-11-752600. Epub 2016 Dec 27. No abstract available.

PMID:
28028024
22.

Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial.

Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, Finetti M, Cumetti D, Carobbio A, Ruperto N, Marcolongo R, Lorini M, Rimini A, Valenti A, Erre GL, Sormani MP, Belli R, Gaita F, Martini A.

JAMA. 2016 Nov 8;316(18):1906-1912. doi: 10.1001/jama.2016.15826.

23.

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients.

De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Barbui T.

Blood Cancer J. 2016 Nov 4;6(11):e493. doi: 10.1038/bcj.2016.103.

24.

The effect of arterial hypertension on thrombosis in low-risk polycythemia vera.

Barbui T, Vannucchi AM, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Ruggeri M, Randi ML, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Thiele J, Pardanani A, Tefferi A.

Am J Hematol. 2017 Jan;92(1):E5-E6. doi: 10.1002/ajh.24583. No abstract available.

25.

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.

De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Rossi E, Betti S, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola R, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Sant'Antonio E, Vannucchi AM, Barbui T.

Leukemia. 2016 Oct;30(10):2032-2038. doi: 10.1038/leu.2016.85. Epub 2016 Apr 26.

PMID:
27113812
26.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A.

Blood Cancer J. 2015 Nov 27;5:e369. doi: 10.1038/bcj.2015.94. No abstract available.

27.

The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.

Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M.

Ann Oncol. 2015 Sep;26(9):1980-7. doi: 10.1093/annonc/mdv255. Epub 2015 Jun 2.

PMID:
26037795
28.

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.

Barbui T, Vannucchi AM, Carobbio A, Thiele J, Rumi E, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Pieri L, Pardanani A, Passamonti F, Finazzi G, Tefferi A.

Am J Hematol. 2015 May;90(5):434-7. doi: 10.1002/ajh.23970. Epub 2015 Feb 27.

29.

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.

Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, Rambaldi A, Finazzi G, Barosi G, Barbui T.

Leukemia. 2015 May;29(5):1209-10. doi: 10.1038/leu.2014.343. Epub 2014 Dec 8. No abstract available.

PMID:
25482134
30.

The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.

Barbui T, Thiele J, Carobbio A, Vannucchi AM, Tefferi A.

Leukemia. 2015 Apr;29(4):992-3. doi: 10.1038/leu.2014.328. Epub 2014 Nov 26. No abstract available.

PMID:
25425199
31.

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A.

Blood. 2014 Nov 6;124(19):3021-3. doi: 10.1182/blood-2014-07-591610. No abstract available.

PMID:
25377561
32.

Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.

Massi D, Simi L, Sensi E, Baroni G, Xue G, Scatena C, Caldarella A, Pinzani P, Fontanini G, Carobbio A, Urso C, Mandalà M.

Mod Pathol. 2015 Apr;28(4):487-97. doi: 10.1038/modpathol.2014.137. Epub 2014 Oct 24.

33.

Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.

Finazzi G, Carobbio A, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM, Cazzola M, Passamonti F, Rambaldi A, Barbui T.

Blood. 2014 Oct 16;124(16):2611-2. doi: 10.1182/blood-2014-08-596676. No abstract available.

PMID:
25323688
34.

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.

Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Rulli E, Deaglio S, Mandalà M.

Ann Oncol. 2014 Dec;25(12):2433-42. doi: 10.1093/annonc/mdu452. Epub 2014 Sep 15.

PMID:
25223485
35.

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

Lussana F, Carobbio A, Randi ML, Elena C, Rumi E, Finazzi G, Bertozzi I, Pieri L, Ruggeri M, Palandri F, Polverelli N, Elli E, Tieghi A, Iurlo A, Ruella M, Cazzola M, Rambaldi A, Vannucchi AM, Barbui T.

Br J Haematol. 2014 Nov;167(4):541-6. doi: 10.1111/bjh.13080. Epub 2014 Aug 16.

PMID:
25130523
36.

Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.

Martinelli I, De Stefano V, Carobbio A, Randi ML, Santarossa C, Rambaldi A, Finazzi MC, Cervantes F, Arellano-Rodrigo E, Rupoli S, Canafoglia L, Tieghi A, Facchini L, Betti S, Vannucchi AM, Pieri L, Cacciola R, Cacciola E, Cortelezzi A, Iurlo A, Pogliani EM, Elli EM, Spadea A, Barbui T.

Am J Hematol. 2014 Nov;89(11):E200-5. doi: 10.1002/ajh.23809. Epub 2014 Jul 31.

37.

Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.

Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A.

Leukemia. 2014 Oct;28(10):2092-4. doi: 10.1038/leu.2014.175. Epub 2014 Jun 3. No abstract available.

PMID:
24888272
38.

Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI).

Rizzi M, Ravasio V, Carobbio A, Mattucci I, Crapis M, Stellini R, Pasticci MB, Chinello P, Falcone M, Grossi P, Barbaro F, Pan A, Viale P, Durante-Mangoni E; Investigators of the Italian Study on Endocarditis.

BMC Infect Dis. 2014 Apr 29;14:230. doi: 10.1186/1471-2334-14-230.

39.

Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.

Barbui T, Thiele J, Carobbio A, Guglielmelli P, Rambaldi A, Vannucchi AM, Tefferi A.

Am J Hematol. 2014 Jun;89(6):588-90. doi: 10.1002/ajh.23694. Epub 2014 Mar 3.

40.

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N.

Haematologica. 2014 May;99(5):916-21. doi: 10.3324/haematol.2013.094284. Epub 2014 Jan 3.

41.

Masked polycythemia vera diagnosed according to WHO and BCSH classification.

Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E, Luigia Randi M, Vannucchi AM, Gisslinger B, Müllauer L, Ruggeri M, Rambaldi A, Tefferi A.

Am J Hematol. 2014 Feb;89(2):199-202. doi: 10.1002/ajh.23617.

42.

Masked polycythemia vera (mPV): results of an international study.

Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, Luigia Randi M, Bertozzi I, Vannucchi AM, Pieri L, Carrai V, Gisslinger B, Müllauer L, Ruggeri M, Rambaldi A, Tefferi A.

Am J Hematol. 2014 Jan;89(1):52-4. doi: 10.1002/ajh.23585. Epub 2013 Sep 19. Erratum in: Am J Hematol. 2018 May;93(5):E133.

43.

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.

Barbui T, Carobbio A, Finazzi G, Guglielmelli P, Salmoiraghi S, Rosti V, Rambaldi A, Vannucchi AM, Barosi G.

Leukemia. 2013 Oct;27(10):2084-6. doi: 10.1038/leu.2013.207. Epub 2013 Jul 5. No abstract available.

PMID:
23828261
44.

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T.

Leukemia. 2013 Sep;27(9):1874-81. doi: 10.1038/leu.2013.163. Epub 2013 Jun 6.

45.

Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.

Ruella M, Salmoiraghi S, Risso A, Carobbio A, Buttiglieri S, Spatola T, Sivera P, Ricca I, Barbui T, Tarella C, Rambaldi A.

Exp Hematol. 2013 Jul;41(7):627-34. doi: 10.1016/j.exphem.2013.03.007. Epub 2013 Mar 28.

PMID:
23542632
46.

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).

Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A.

Blood. 2012 Dec 20;120(26):5128-33; quiz 5252. doi: 10.1182/blood-2012-07-444067. Epub 2012 Oct 1.

PMID:
23033268
47.

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A.

Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26.

PMID:
22740446
48.

Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.

Barbui T, Thiele J, Carobbio A, Passamonti F, Rumi E, Randi ML, Bertozzi I, Vannucchi AM, Gisslinger H, Gisslinger B, Finazzi G, Ruggeri M, Rodeghiero F, Rambaldi A, Gangat N, Tefferi A.

Blood. 2012 Jul 19;120(3):569-71. doi: 10.1182/blood-2012-01-407981. Epub 2012 Jun 13.

PMID:
22700720
49.

Full-right-full-left split liver transplantation: the retrospective analysis of an early multicenter experience including graft sharing.

Zambelli M, Andorno E, De Carlis L, Rossi G, Cillo U, De Feo T, Carobbio A, Giacomoni A, Bottino G, Colledan M.

Am J Transplant. 2012 Aug;12(8):2198-210. doi: 10.1111/j.1600-6143.2012.04071.x. Epub 2012 May 11.

50.

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients.

Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Müllauer L, Frantal S, Carobbio A, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Finazzi G, Gangat N, Tefferi A, Barbui T.

Am J Hematol. 2012 Jul;87(7):669-72. doi: 10.1002/ajh.23217. Epub 2012 May 10.

Supplemental Content

Loading ...
Support Center